RxDoctor Payments Data

Tamara McCue, DO

Family Medicine · Wellington, KSNPI 1457339137

Payments from drug & device makers

$613in general payments, 2019–2025

Across 42 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$148
  • Teva Pharmaceuticals USA, Inc.$134
  • Neurocrine Biosciences, Inc.$90
  • Novartis$74
  • Avanir Pharmaceuticals, Inc.$59
  • Astellas Pharma US Inc$59
  • plus $49 from 4 others

What the payments were for

  • Food & beverage$50482%
  • Education$10918%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$613 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$387,466
Medicare patients
1,228
Services billed
3,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,125$704,086
IngrezzaValbenazine Tosylate49$265,950
XareltoRivaroxaban301$95,563
MyrbetriqMirabegron495$87,202
JanuviaSitagliptin Phosphate226$79,644
TradjentaLinagliptin267$71,552
Potassium Chloride2,482$68,729
OzempicSemaglutide64$66,153
JardianceEmpagliflozin167$64,949
NuplazidPimavanserin Tartrate23$57,169
Risperdal ConstaRisperidone Microspheres25$56,269
XifaxanRifaximin21$56,264
Invega SustennaPaliperidone Palmitate22$54,617
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$50,928
FarxigaDapagliflozin Propanediol136$45,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$90$265,95049 claims
Johnson & JohnsonXarelto, Risperdal Consta, Invega Sustenna$11$206,449348 claims
Astellas Pharma US IncMyrbetriq$59$87,202495 claims
Avanir Pharmaceuticals, Inc.Nuedexta$59$35,44141 claims
NovartisEntresto$74$34,58885 claims
Lilly USA, LLCTrulicity$12$25,74726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Wellington

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →